A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM)

Documenti analoghi

• Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
  di: Cluzeau, Thomas, et al.
  Pubblicazione: (2021)
• Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies
  di: Adès, Lionel, et al.
  Pubblicazione: (2012)
• Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies
  di: Kelaidi, Charikleia, et al.
  Pubblicazione: (2010)
• Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies
  di: Ades, Lionel, et al.
  Pubblicazione: (2017)
• Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
  di: Raj, Kavita, et al.
  Pubblicazione: (2006)